291 related articles for article (PubMed ID: 17529888)
1. Saliva and serum levetiracetam concentrations in patients with epilepsy.
Mecarelli O; Li Voti P; Pro S; Romolo FS; Rotolo M; Pulitano P; Accornero N; Vanacore N
Ther Drug Monit; 2007 Jun; 29(3):313-8. PubMed ID: 17529888
[TBL] [Abstract][Full Text] [Related]
2. In situ metabolism of levetiracetam in blood of patients with epilepsy.
Patsalos PN; Ghattaura S; Ratnaraj N; Sander JW
Epilepsia; 2006 Nov; 47(11):1818-21. PubMed ID: 17116020
[TBL] [Abstract][Full Text] [Related]
3. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of oral loading of levetiracetam.
Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
[TBL] [Abstract][Full Text] [Related]
5. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Plasma, Saliva, and Hair Levetiracetam Concentrations.
Karaś-Ruszczyk K; Kuczyńska J; Sienkiewicz-Jarosz H; Kurkowska-Jastrzębska I; Bienkowski P; Restel M; Samochowiec J; Mierzejewski P
Ther Drug Monit; 2017 Jun; 39(3):263-268. PubMed ID: 28490049
[TBL] [Abstract][Full Text] [Related]
7. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
10. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials.
Gidal BE; Baltès E; Otoul C; Perucca E
Epilepsy Res; 2005; 64(1-2):1-11. PubMed ID: 15823510
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam: a new therapeutic option for refractory epilepsy.
Pinto A; Sander JW
Int J Clin Pract; 2003 Sep; 57(7):616-21. PubMed ID: 14529064
[TBL] [Abstract][Full Text] [Related]
13. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
14. Quantification of levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: application to therapeutic drug monitoring.
Matar KM
J Pharm Biomed Anal; 2008 Nov; 48(3):822-8. PubMed ID: 18603399
[TBL] [Abstract][Full Text] [Related]
15. Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring.
Vasudev A; Tripathi KD; Puri V
Neurol India; 2002 Mar; 50(1):60-2. PubMed ID: 11960153
[TBL] [Abstract][Full Text] [Related]
16. Disfluent speech in patients with partial epilepsy: beneficial effect of levetiracetam.
Sechi G; Cocco GA; D'Onofrio M; Deriu MG; Rosati G
Epilepsy Behav; 2006 Nov; 9(3):521-3. PubMed ID: 16971185
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam use in pregnancy.
Longo B; Forinash AB; Murphy JA
Ann Pharmacother; 2009 Oct; 43(10):1692-5. PubMed ID: 19690219
[TBL] [Abstract][Full Text] [Related]
18. Correlation of levetiracetam concentrations between serum and saliva.
Grim SA; Ryan M; Miles MV; Tang PH; Strawsburg RH; deGrauw TJ; Fakhoury TA; Baumann RJ
Ther Drug Monit; 2003 Feb; 25(1):61-6. PubMed ID: 12548146
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy.
Contin M; Mohamed S; Albani F; Riva R; Baruzzi A
Epilepsy Res; 2012 Feb; 98(2-3):130-4. PubMed ID: 21944894
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy.
Piazzini A; Chifari R; Canevini MP; Turner K; Fontana SP; Canger R
Epilepsy Res; 2006 Mar; 68(3):181-8. PubMed ID: 16332430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
